Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B antigen + eftilagimod alpha
- Development stage
- Unknown
- Lead developer
- Immutep
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
A combination of hepatitis B antigen (used in vaccines to induce immunity against the hepatitis B virus) and eftilagimod alpha (IMP321), a soluble LAG-3 fusion protein that acts as an immune checkpoint modulator. Eftilagimod alpha is designed to activate antigen-presenting cells by binding to MHC class II molecules and stimulating T cell responses. It is being developed primarily as an immunotherapy adjuvant in cancer settings but has also been investigated for use with antigens such as those from the hepatitis B virus. The combination aims to enhance immune responses against the target pathogen or tumor by increasing both innate and adaptive immunity[1][2]. Eftilagimod alpha is developed by Immutep and has been studied in various cancers; its development for hepatitis B was discontinued[2].
- Brand names
- ImmuFact
- Other names
- hepatitis B antigen + IMP321hepatitis B antigen + efti
02
Targets
MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on hepatitis B antigen + eftilagimod alpha.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B antigen + eftilagimod alpha.